男性膀胱过度活动症。
Overactive bladder in males.
机构信息
Professor, Department of Urologic Surgery, Vanderbilt University Medical Center, A-1392, Medical Center North, Nashville, TN 37232, USA.
出版信息
Ther Adv Urol. 2009 Oct;1(4):209-21. doi: 10.1177/1756287209350383.
Abstract
The prevalence of overactive bladder (OAB) symptoms is considerable in both men and women and the impact on quality of life (QOL) is equally substantial. Ironically, despite nearly equal prevalence, OAB symptoms in men are infrequently treated, and often with medical therapies aimed at bladder outlet obstruction (BOO). In this review, we examine the pathophysiology of OAB and its evaluation in the context of benign prostatic hypertrophy and concomitant BOO. We then consider the efficacy and safety of individual therapeutic options for lower urinary tract symptoms in men, focusing on the mainstays of medical therapy: α-adrenergic blockers, 5-α reductase inhibitors, and antimuscarinic agents. Finally, we aim to comment on new therapeutic strategies and targets that may one day be available for the treatment of male OAB.
摘要
膀胱过度活动症（OAB）的症状在男性和女性中都相当普遍，对生活质量（QOL）的影响同样巨大。具有讽刺意味的是，尽管患病率几乎相等，但男性的 OAB 症状很少得到治疗，而且通常采用针对膀胱出口梗阻（BOO）的医学治疗方法。在这篇综述中，我们检查了 OAB 的病理生理学及其在良性前列腺增生和伴随的 BOO 中的评估。然后，我们考虑了男性下尿路症状的个别治疗选择的疗效和安全性，重点是医学治疗的主要方法：α-肾上腺素能阻滞剂、5-α 还原酶抑制剂和抗毒蕈碱药物。最后，我们旨在评论新的治疗策略和靶点，这些策略和靶点有朝一日可能可用于治疗男性 OAB。
相似文献
1
Overactive bladder in males.
Ther Adv Urol. 2009 Oct;1(4):209-21. doi: 10.1177/1756287209350383.
2
Diagnosis and treatment of lower urinary tract symptoms suggestive of overactive bladder and bladder outlet obstruction among men in general practice in the UK.
Int J Clin Pract. 2008 May;62(5):688-94. doi: 10.1111/j.1742-1241.2008.01737.x. Epub 2008 Mar 17.
3
The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update.
Eur Urol. 2011 Jul;60(1):94-105. doi: 10.1016/j.eururo.2011.03.054. Epub 2011 Apr 9.
4
Safety and efficacy of an α -blocker plus mirabegron compared with an α -blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: A systematic review and network meta-analysis.
Neurourol Urodyn. 2024 Mar;43(3):604-619. doi: 10.1002/nau.25399. Epub 2024 Jan 30.
5
Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder.
BJU Int. 2004 Oct;94(6):817-20. doi: 10.1111/j.1464-410X.2004.05039.x.
6
Refractory overactive bladder in men: update on novel therapies.
Curr Urol Rep. 2006 Nov;7(6):456-61. doi: 10.1007/s11934-006-0054-5.
7
Occurrence of overactive bladder in patients with benign prostatic hyperplasia in the Czech Republic.
Urol Int. 2011;86(4):407-13. doi: 10.1159/000320996. Epub 2011 Apr 1.
8
Mirabegron for male lower urinary tract symptoms.
Curr Urol Rep. 2013 Dec;14(6):580-4. doi: 10.1007/s11934-013-0363-4.
9
Place of overactive bladder in male lower urinary tract symptoms.
World J Urol. 2009 Dec;27(6):723-8. doi: 10.1007/s00345-009-0470-5.
10
Overactive bladder and outlet obstruction in men.
Curr Urol Rep. 2011 Feb;12(1):77-85. doi: 10.1007/s11934-010-0157-x.
引用本文的文献
1
Barriers to early and effective overactive bladder management in male patients with lower urinary tract symptoms.
PLoS One. 2025 Jul 23;20(7):e0328723. doi: 10.1371/journal.pone.0328723. eCollection 2025.
2
Cannabis Use is Associated With Lower Urinary Tract Symptoms in Pediatric Patients-A Large Claims Database Study.
Urology. 2025 Jul 15. doi: 10.1016/j.urology.2025.07.014.
3
Cutting-edge assays for mirabegron and tadalafil combo therapy for benign prostatic hyperplasia; insilico kinetics approach; multi trait sustainability assessment.
BMC Chem. 2025 May 23;19(1):140. doi: 10.1186/s13065-025-01497-z.
4
Adverse Effects of Intravesical OnabotulinumtoxinA Injection in Patients with Idiopathic Overactive Bladder or Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Studies.
Toxins (Basel). 2024 Aug 5;16(8):343. doi: 10.3390/toxins16080343.
5
Anesthetic options for Rezūm water vapor therapy Is minimal sedation tolerable for a minimally invasive procedure?
Can Urol Assoc J. 2024 May;18(5):E137-E141. doi: 10.5489/cuaj.8535.
6
PATTERN OF OVERACTIVE BLADDER IN SOUTHEAST NIGERIA.
J West Afr Coll Surg. 2014 Jul-Sep;4(3):100-20.
7
Inhibition of NMDAR reduces bladder hypertrophy and improves bladder function in cyclophosphamide induced cystitis.
J Urol. 2015 May;193(5):1676-83. doi: 10.1016/j.juro.2014.12.092. Epub 2015 Jan 6.
8
Usage results of a mobile app for managing urinary incontinence.
J Urol. 2015 Apr;193(4):1292-7. doi: 10.1016/j.juro.2014.10.009. Epub 2014 Oct 13.
9
Current role of treatment in men with lower urinary tract symptoms combined with overactive bladder.
Prostate Int. 2014;2(2):43-9. doi: 10.12954/PI.14045. Epub 2014 Jun 30.
10
Efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle-aged patients: a single-blinded, prospective, multi-center study.
Int Neurourol J. 2011 Sep;15(3):172-5. doi: 10.5213/inj.2011.15.3.172. Epub 2011 Sep 30.
本文引用的文献
1
Signs and symptoms that distinguish detrusor underactivity from mixed detrusor underactivity and bladder outlet obstruction in male patients.
Neurourol Urodyn. 2018 Apr;37(4):1501-1505. doi: 10.1002/nau.23492. Epub 2018 Jan 22.
2
Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
Scand J Urol Nephrol. 2009;43(4):307-14. doi: 10.1080/00365590902836740.
3
Bother related to bladder control and health care seeking behavior in adults in the United States.
J Urol. 2009 Jun;181(6):2591-8. doi: 10.1016/j.juro.2009.02.018. Epub 2009 Apr 16.
4
Efficacy of combined amlodipine/terazosin therapy in male hypertensive patients with lower urinary tract symptoms: a randomized, double-blind clinical trial.
Urology. 2009 Jul;74(1):130-6. doi: 10.1016/j.urology.2008.11.051. Epub 2009 Apr 15.
5
Impact of overactive bladder on work productivity in the United States: results from EpiLUTS.
Am J Manag Care. 2009 Mar;15(4 Suppl):S98-S107.
6
Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder.
Eur Urol. 2009 Jul;56(1):14-20. doi: 10.1016/j.eururo.2009.02.026. Epub 2009 Mar 3.
7
Obstructive sleep apnea syndrome is associated with overactive bladder and urgency incontinence in men.
Sleep. 2009 Feb;32(2):271-5. doi: 10.1093/sleep/32.2.271.
8
Evaluation and treatment of lower urinary tract symptoms in older men.
J Urol. 2009 Apr;181(4):1779-87. doi: 10.1016/j.juro.2008.11.127. Epub 2009 Feb 23.
9
Nocturia: a non-specific but important symptom of urological disease.
Int J Urol. 2009 Mar;16(3):249-56. doi: 10.1111/j.1442-2042.2008.02246.x. Epub 2009 Feb 17.
10
Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
Urology. 2008 Nov;72(5):1061-7; discussion 1067. doi: 10.1016/j.urology.2008.06.067. Epub 2008 Sep 25.
Zotero 插件